Indication

B-cell Non-Hodgkin Lymphoma

Clinical and regulatory intelligence for B-cell Non-Hodgkin Lymphoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 1

Relevant assets

DZD8586 →

Relevant companies

Dizal Pharmaceuticals →

Recent signals(2)

ClinicalJuly 4, 2026

Study on CD3-CD20 Bispecific Antibody with CD19-CAR T Cells in B-NHL

A clinical study is underway to evaluate the safety and efficacy of CD3-CD20 bispecific antibody therapy combined with CD19-CAR T cells in relapsed refractory B-NHL.

ClinicalJuly 3, 2026

Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma

Dizal Pharmaceuticals is conducting a study on DZD8586 for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

B-cell Non-Hodgkin Lymphoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.